S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Zacks: Brokerages Expect Vericel Co. (NASDAQ:VCEL) Will Announce Quarterly Sales of $38.17 Million

Last updated on Saturday, May 14, 2022 | 2022 MarketBeat

Wall Street brokerages expect that Vericel Co. (NASDAQ:VCEL - Get Rating) will announce sales of $38.17 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vericel's earnings. The lowest sales estimate is $37.59 million and the highest is $39.01 million. Vericel posted sales of $39.52 million during the same quarter last year, which suggests a negative year over year growth rate of 3.4%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Vericel will report full year sales of $184.18 million for the current financial year, with estimates ranging from $181.88 million to $186.59 million. For the next year, analysts forecast that the business will post sales of $228.37 million, with estimates ranging from $220.40 million to $233.12 million. Zacks' sales calculations are a mean average based on a survey of research analysts that follow Vericel.

Vericel (NASDAQ:VCEL - Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Vericel had a negative return on equity of 6.93% and a negative net margin of 7.15%. The business had revenue of $36.07 million during the quarter, compared to analyst estimates of $34.31 million. During the same period in the prior year, the firm earned ($0.07) EPS. The business's revenue for the quarter was up 4.4% on a year-over-year basis.


Several brokerages have commented on VCEL. Zacks Investment Research upgraded shares of Vericel from a "sell" rating to a "hold" rating in a report on Tuesday. SVB Leerink raised their target price on shares of Vericel from $40.00 to $45.00 and gave the stock an "outperform" rating in a report on Friday, February 25th. StockNews.com began coverage on shares of Vericel in a report on Thursday, March 31st. They issued a "sell" rating for the company. Finally, TheStreet cut shares of Vericel from a "c-" rating to a "d+" rating in a report on Thursday, March 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $48.50.

In related news, Director Steven C. Gilman sold 900 shares of the firm's stock in a transaction that occurred on Friday, April 29th. The shares were sold at an average price of $30.94, for a total transaction of $27,846.00. Following the completion of the sale, the director now directly owns 5,200 shares in the company, valued at $160,888. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 5.20% of the company's stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Pinebridge Investments L.P. acquired a new stake in Vericel in the fourth quarter valued at approximately $31,000. Fifth Third Bancorp lifted its stake in Vericel by 102.0% in the first quarter. Fifth Third Bancorp now owns 1,283 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 648 shares during the last quarter. Capital Advisory Group Advisory Services LLC bought a new position in shares of Vericel in the first quarter valued at approximately $76,000. Captrust Financial Advisors raised its position in shares of Vericel by 186.0% in the third quarter. Captrust Financial Advisors now owns 2,362 shares of the biotechnology company's stock valued at $115,000 after purchasing an additional 1,536 shares during the period. Finally, Hardy Reed LLC bought a new position in shares of Vericel in the first quarter valued at approximately $103,000.

Shares of VCEL opened at $28.30 on Friday. Vericel has a one year low of $25.11 and a one year high of $68.94. The company has a 50-day moving average of $34.31 and a two-hundred day moving average of $37.19. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -113.20 and a beta of 1.96.

About Vericel (Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

See Also

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Vericel right now?

Before you consider Vericel, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.

While Vericel currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.